secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001193125-23-132450
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q1 net sales $71.7M (+21.7% YoY); net loss narrows to $5.0M; Adj. EBITDA $5.5M
--------------------------------------------------------------------------------

- Net sales $71.7M in Q1 2023, up 21.7% from $58.9M in Q1 2022.
- Net loss improved to $5.0M from $10.5M in prior year; Adjusted EBITDA of $5.5M.
- CEO attributed growth to robust demand for new surgical products and accelerated growth in private physician offices.
- Gross margin improved sequentially; operating expenses grew slower than sales.
- Company also announced an upcoming Chief Financial Officer transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312523132450/0001193125-23-132450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312523132450/d79375d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-132450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer